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Abstract
Electronic nicotine and non-nicotine delivery systems (EN&NNDS) are a heterogeneous class of products that 
use an electrically powered coil to heat and turn a liquid into an aerosol, which is inhaled by the user. EN&NNDS 
are not harmless. Although the consequences for long-term effects on morbidity and mortality have not yet been 
studied sufficiently, EN&NNDS are not safe for young people, pregnant women and adults who have never smoked. 
While it is expected that use of EN&NNDS in these groups might increase their health risks, non-pregnant adult 
smokers who completely and promptly switch from combustible tobacco cigarettes to use of unadulterated and 
appropriately regulated EN&NNDS alone might reduce their health risks. Member States that decide to regulate 
EN&NNDS may consider, inter alia: regulating EN&NNDS that make health claims as medicinal products and 
therapeutic devices; banning or restricting advertising, promotion and sponsorship of EN&NNDS; minimizing 
health risks to non-users by outlawing the use of EN&NNDS in all indoor spaces or where smoking is prohibited; 
and limiting the level and number of specific flavours allowed in EN&NNDS to reduce initiation by young people.
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Electronic nicotine 
and non-nicotine 
delivery systems 
Electronic nicotine and non-nicotine delivery systems (EN&NNDS)1 are a 
heterogeneous class of products that use an electrically powered coil to heat 
and turn a liquid into an aerosol, which is inhaled by the user. 
The generation and composition of aerosol during EN&NNDS use or so-called 
vaping and the subsequent exposure to aerosol substances is determined by 
four factors: 
1_ the e-liquid composition
2_ the materials used in manufacturing the device 
3_ the electrical power or wattage used during operation to heat the e-liquid 
4_ the puffing topography or inhaling characteristics of the user while using 
EN&NNDS. 
E-liquids always contain carrier liquids (humectants) which comprise 80–90% 
of the volume of the liquid, some water (10–20% of the volume) and, generally, 
nicotine and flavours. Propylene glycol and glycerol, the principal carriers 
used in e-liquids, undergo partial decomposition in contact with the atomizer 
heating coil, forming several toxicants, including carbonyls. E-liquids may also 
contain nicotine, a highly addictive substance, that may adversely affect fetal 
and adolescent brain development. 
Heating elements or coils in EN&NNDS are usually made of resistance wires 
of various metals, such as nickel, or metal alloys, including nichrome (chrome 
and nickel). Metal parts of the device are sometimes soldered with lead.
To heat and aerosolize the e-liquid, an electrical current from a battery is run 
through the coil when the EN&NNDS is activated. The temperature reached 
depends on the electrical power generated, which in turn depends on the 
amount of energy provided by the battery and the resistance of the coil. The 
lower the resistance, the more electricity flows through it, and the more heat is 
generated at the coil. Under normal operation conditions, the e-liquid reaches 
a temperature of between 100–350 °C. 
The inhaling behaviour or puffing topography of users has the following 
variables: puff volume, depth of inhalation, rate of puffing, and intensity of 
puffing. These variables determine the amount of aerosol inhaled and how 
deep it is carried into the respiratory system.
1 This brief follows the terminology of the Conference of the Parties of the WHO Framework Convention on Tobacco 
Control by referring to electronic nicotine delivery systems (ENDS) for products in which the e-liquid contains nicotine and 
electronic non-nicotine delivery systems (ENNDS) for those in which it does not. These systems are referred to collectively 
as electronic nicotine and non-nicotine delivery systems (EN&NNDS). They are popularly known as electronic cigarettes 
or e-cigarettes. Other sources refer to ENDS as alternative nicotine delivery systems (ANDS).
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EN&NNDS use 
among the 
population
Proportion of the adult population using 
EN&NNDS regularly 
The proportion of adults who currently (defined as at least once in the last 
month) used EN&NNDS in the two main world markets for these products, the 
United States of America and the European Union (EU), was 3.2% in 2018 (1) 
and 2% in 2017 (2) respectively. Highest prevalence of use among EU countries 
in 2018 was in the United Kingdom (England), at 6.2% (3). In New Zealand, 
3.8% of adults currently used EN&NNDS in 2017–2018 (4). Additional data 
from nine countries indicate that in most, no more than 4% of adults used 
EN&NNDS regularly between 2017 and 2018 (5).
Very few countries have trend data. The proportion of current adult users of 
EN&NNDS in the United States has remained stable since 2014 (at 3.7%) (1) 
and in the EU since 2015 (2%) (6). In Canada, past 30-day use and daily use 
of EN&NNDS among adults remained stable in the period between 2013 and 
2017 (7). Only New Zealand shows a clear increase of use of EN&NNDS among 
adults, from 1.4% in 2015–2016 to 3.8% in 2017–2018 and 4.7% in 2018–2019 
(4). Most EN&NNDS users are or were smokers. 
Proportion of young people using EN&NNDS 
regularly 
Data on the current use of EN&NNDS among young people aged 13–15 years 
from 22 countries indicate that the proportion using EN&NNDS regularly is 
higher than among their adult counterparts. Figures for young people ranged 
from 0.7% in Japan to 18.4% in Ukraine between 2017 and 2019, with a median 
country value of 8.1% (8).
Between 2008 and 2015, ever using EN&NNDS among young people increased 
in Poland, New Zealand, the Republic of Korea and the United States, decreased 
in Canada and Italy, and remained stable in the United Kingdom (9). Current 
use of EN&NNDS among 11–18-year-olds in the United States increased from 
2017 to 2018 (10) while remaining stable in the United Kingdom. In 2019, 
1.6% of 11–18-year-olds in the United Kingdom used EN&NNDS more than 
once a week, compared to 1.7% in 2018 (11). In Canada, past 30-day use of 
EN&NNDS among young people in grades 7–9 was 5.4% in 2016–2017, which 
was not significantly different from use in 2014–2015 (12). A recent study 
comparing the change in EN&NNDS use among 16–19-year-olds in Canada, 
the United Kingdom (England) and the United States between 2017 and 2018 
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confirmed the increase of EN&NNDS use in Canada and the United States 
and the stability in the United Kingdom (England) for use during the past 30 
days and past week (Table 1) (13).
EN&NNDS
use during:
Canada United States United Kingdom (England)
2017 (%) 2018 (%) 2017 (%) 2018 (%) 2017 (%) 2018 (%)
past 30 days 8.4 14.6 11.1 16.2 8.7 8.9
past week 5.2  9.3  6.4 10.6 4.6 4.6
Source: Hammond et al. (13).
EN&NNDS current use among non-smoking 
young people
Data from the United States show that in 2017, 0.8% of all 11–18-year-olds 
who had never smoked a cigarette before were using EN&NNDS regularly 
(at least once in the last 10 days). In 2018, the proportion increased to 2.4% 
(14). In the United Kingdom (England), however, 0.8% of young people aged 
11–18 years who had never smoked were currently using EN&NNDS (3). 
Weekly use of EN&NNDS among never-smokers aged 17 and 18 years was 
0% in 2016 and 2017 (15) and 0.2% in 2018 (3). The recent study comparing 
the change in EN&NNDS use among 16–19-year-olds in Canada, the United 
Kingdom (England) and the United States between 2017 and 2018 confirmed 
the increasing number of never-smokers using EN&NNDS during the past 30 
days and the past week in Canada and the United States, while the figure did 
not change in the United Kingdom (England) (Table 2) (13). 
EN&NNDS
use during:
Canada United States United Kingdom (England)
2017 (%) 2018 (%) 2017 (%) 2018 (%) 2017 (%) 2018 (%)
past 30 days 2.3 5.0 2.4 5.9 1.6 1.9
past week 0.8 2.7 1.1 3.0 0.5 0.4
Source: Hammond et al. (13).
TABLE 2. Prevalence change of 
current EN&NNDS use among 
16–19-year-old never-smokers 
between 2017 and 2018 in three 
countries 
TABLE 1. Prevalence change of 
current EN&NNDS use among 
16–19-year-olds between 2017 
and 2018 in three countries
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EN&NNDS 
contents and 
health effects
EN&NNDS aerosol contents 
The aerosol users breathe from EN&NNDS contains numerous potentially 
toxic substances, in addition to nicotine when included in the e-liquid. The 
number, quantity and characteristics of potentially toxic substances in the 
aerosol emitted by EN&NNDS are highly variable and depend on product 
characteristics (including device and e-liquid features) and how the device is 
operated by the user. Under typical conditions of use, however, the number 
and concentrations of potentially toxic substances emitted from unadulterated 
EN&NNDS are lower than in tobacco smoke, except for some metals. 
The main substances in the aerosol that raise health concern are metals, 
such as chromium, nickel, and lead, and carbonyls, such as formaldehyde, 
acetaldehyde, acrolein and glyoxal.
The types and concentrations of metals depend on the product features and 
inhaling patterns of use. Exposure to certain levels of some metals may cause 
serious health effects, such as diseases of the nervous, cardiovascular and 
respiratory systems. The number of metals in the aerosol could be greater 
than in combustible tobacco cigarettes, and in some cases is found at higher 
concentrations than in cigarette smoke. It is suspected that metals come 
mostly from the metallic coil used to heat the e-liquid and soldered joints 
of the device. Metal emissions can largely be prevented through appropriate 
engineering of devices. 
Carbonyl compounds are potentially hazardous to users. Formaldehyde is a 
human carcinogen, acetaldehyde is possibly carcinogenic to humans, acrolein 
is a strong irritant of the respiratory system and glyoxal shows mutagenicity. 
Most carbonyls come from the thermal decomposition of humectants, 
propylene glycol and glycerol. The number and levels of carbonyls detected 
in the aerosol are lower than in smoke from combustible tobacco, but even 
these levels raise health concerns. 
Other substances in the aerosol of possible health concern are particulate 
matter and some flavourings.
The particle count and size in EN&NNDS aerosols do not differ greatly from 
those found in mainstream combustible tobacco smoke. The composition of the 
particles nevertheless is dissimilar and likely to have a different health impact. 
Aerosol particulates from EN&NNDS consist mostly of a mix of aqueous and 
humectant droplets, whereas particles in combustible tobacco smoke are mostly 
complex organic constituents that contain known or suspected carcinogens. 
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Although of health concern, particles from EN&NNDS are therefore expected 
to have smaller health risks than particles in tobacco smoke.
Certain flavourings, such as diacetyl, cinnamaldehyde and benzaldehyde, 
have been cited as a source of health concerns when heated and inhaled. 
When the e-liquid contains nicotine, the aerosol contains nicotine. The amount 
of nicotine inhaled by ENDS users is highly variable and depends on product 
characteristics (including device and e-liquid characteristics) and how the 
device is operated. There is substantial evidence that nicotine intake from 
ENDS among experienced adult ENDS users can be comparable to that from 
combustible tobacco cigarettes.
Health effects of using EN&NNDS
Scientists are still learning about the long-term health effects of EN&NNDS. 
Currently, there is insufficient research to determine with certainty whether 
unadulterated and appropriately regulated EN&NNDS use is associated with 
cardiovascular, lung or cancer diseases. 
The following section describes what currently is known by strength of 
evidence,2 as assessed by the National Academies of Sciences, Engineering 
and Medicine (NASEM) in 2018 (16). 
There is conclusive evidence that: 
 completely substituting EN&NNDS for combustible tobacco cigarettes 
reduces users’ exposure to numerous toxicants and carcinogens present 
in combustible tobacco cigarettes;
 EN&NNDS devices can explode and cause burns and projectile injuries 
when batteries are of poor quality, stored improperly or modified by users; 
and
 intentional or accidental exposure to e-liquids (from drinking, eye contact 
or dermal contact) can result in adverse health effects, sometimes fatal.
There is substantial evidence that: 
 ENDS use results in symptoms of nicotine dependence – the risk and 
severity of nicotine dependence are influenced by the ENDS product 
characteristics (nicotine concentration, flavouring, device type and brand), 
but the risk and severity of dependence seem lower for ENDS than from 
combustible tobacco cigarettes;
2 Only conclusions for which the NASEM deems there to be conclusive, substantial and moderate evidence are presented, 
not evidence with limited, insufficient or no available proof. Conclusive, substantial and moderate scientific evidence allows 
firm conclusions, firm conclusions with minor limitations, and a general conclusion with limitations, respectively. Strength 
of evidence refers to the certainty of an association but not necessarily to its magnitude. The strength of using reliable 
literature reviews, such as the one from NASEM, is that their conclusions are based on the systematic and methodical 
overview of consolidated evidence at the moment of the review, 2018 in this case. Research on EN&NNDS is developing 
rapidly, however, which means that some new studies may contradict the conclusions of systematic reviews. Findings of 
new studies not yet included in reliable systematic reviews are not discussed here, unless they present overwhelming and 
undisputed evidence. 
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 EN&NNDS aerosol can cause some human cells to malfunction – it is not 
clear what this means in terms of the long-term consequences of chronic 
use of EN&NNDS, but it is possible that it could increase the risk of some 
diseases, such as cardiovascular disease, cancer and adverse reproductive 
outcomes, although the risk is probably lower than from combustible 
tobacco cigarette smoke; and 
 completely switching from regular use of combustible tobacco cigarettes 
to EN&NNDS results in reduced short-term adverse health outcomes in 
several organ systems.
There is moderate evidence that:
 EN&NNDS use increases cough and wheeze in adolescents and is associated 
with an increase in asthma exacerbations; and
 the positive and negative health impacts of EN&NNDS use is applicable 
to the employment of these products in the absence of simultaneous 
consumption of tobacco products, but a significant proportion of EN&NNDS 
users, referred to as dual- or poly-users, also smoke tobacco products. 
The question is – do EN&NNDS users who continue to smoke have any reduction 
in health risk? The NASEM review concluded that there is no available evidence 
on whether long-term e-cigarette use among smokers (dual use) changes 
morbidity or mortality compared with those who only smoke combustible 
tobacco cigarettes. Recent evidence, however, suggests that dual users have 
a greater level of oxidative stress than smokers (17) and that adding use 
of EN&NNDS to smoking may contribute to cardiopulmonary health risks, 
particularly involving the respiratory system (18). 
During the drafting of this brief, the Centers for Disease Control and Prevention 
(CDC) of the United States reported an outbreak of lung disorders associated 
with the use of e-cigarettes and vaping (19). As of 7 January 2020, more than 
2500 cases had been reported to CDC from 50 states. Almost 60 deaths had 
been confirmed in 27 states. 
CDC has identified vitamin E acetate as a chemical of concern among people 
with e-cigarette, or vaping, product-use associated lung injury (EVALI). CDC 
laboratory testing of fluid samples collected from the lungs of 29 patients with 
EVALI submitted from 10 states found vitamin E acetate in all of the samples. 
Vitamin E acetate is used as an additive, most notably as a thickening agent 
in tetrahydrocannabinol-containing e-cigarette, or vaping, products.
A note on the  
cases of lung 
problems linked to 
EN&NNDS use in 
the United States
6 Electronic nicotine and non-nicotine delivery systems: a brief
Another study concludes that dual users are not reducing exposure to harmful 
toxicants compared to exclusive cigarette smokers due to their continued 
smoking (20). A possible explanation is that dual users include a great variety 
of tobacco- and EN&NNDS-use behaviours, each with different motivations 
(21). Dual use may not represent only a transitional phase to reduce or quit 
smoking; this category may also include EN&NNDS users who still rely on 
smoking to manage their dissatisfaction with the EN&NNDS experience, to 
circumvent smoke-free policies or simply to comply with social group norms 
and manage the stigma associated with smoking (22).
Second-hand exposure to EN&NNDS aerosol
EN&NNDS users inhale the aerosol directly from the device and partly exhale it 
back into the air, which bystanders may then breathe in. As a result, EN&NNDS 
use increases airborne concentrations of particulate matter and nicotine 
in indoor environments compared with background levels (16). Some 
studies indicate that some volatile organic compounds are also exhaled into the 
environment during EN&NNDS use. The concentration of these substances in 
the air increases with the number of users in confined spaces. Second-hand 
exposure to nicotine and particulates is lower from EN&NNDS aerosol 
compared with combustible tobacco cigarettes (16) but are higher than 
the smoke-free level recommended by the WHO Framework Convention on 
Tobacco Control (WHO FCTC) (23).
Health effects of exposure to exhaled aerosol
No available studies have evaluated the health effects of second-hand EN&NNDS 
exposure, so the risks to health of exposure to exhaled aerosol remain unknown. 
It is expected, however, to present some health risks for bystanders, although 
at lower levels than from exposure to second-hand tobacco smoke.
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EN&NNDS’  
role in smoking 
cessation and 
initiation
EN&NNDS’ role in smoking cessation among 
adults
The NASEM review concluded that there is insufficient evidence from randomized 
controlled trials about the effectiveness of ENDS as cessation aids compared 
with no treatment or approved smoking-cessation treatments (16), although 
it did not include a recent trial whose results depart from this conclusion (24). 
Moderate evidence, however, shows that some smokers may successfully quit 
tobacco by using some types of ENDS frequently or intensively (16), while 
others experience no difference or are even prevented from quitting (25).
EN&NNDS’ role in smoking initiation among 
young people
There is moderate evidence that young never-smokers who experiment 
with EN&NNDS are at least twice more likely to experiment with smoking 
later (16). The data available so far do not, however, prove that this evident 
association is causal. While some authors believe that ENDS use and smoking 
are initiated independently of each other as the result of a common latent 
propensity to risky behaviour, others think that the similarity between ENDS 
use and smoking facilitates the trajectory from one product to the other within 
a social learning framework.
The role of flavours in EN&NNDS initiation and use
E-liquids for EN&NNDS are marketed in more than 15 000 unique flavours 
(26,27). Flavours are classified in two big groups: tobacco flavours, and those 
that impart a strong non-tobacco smell or taste. The latter are considered 
so-called characterizing flavours, the main categories of which are menthol/
mint, nuts, spices, coffee/tea, alcohol, other beverages, fruit, candy and other 
sweets (28). 
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Flavours are one of the most appealing features of EN&NNDS and have been 
described as the major motivation for ENDS use by young people. They can 
alter expectations and reward from EN&NNDS, including nicotine effects 
(29,30). Advertisements on e-liquid containers and vendor websites frequently 
contain images and descriptions of flavours that convey appealing product 
sensations (31). 
Flavours seem to play a part in promoting the switch from combustible 
tobacco products to EN&NNDS (32–34). They also play an important role 
in increasing uptake of EN&NNDS among young people (35–37), noticeably 
more significantly than among adults (38). The use of flavoured e-liquids is 
generally higher among young people and young adults than in older adults. 
It is also more frequent among non-smokers than conventional cigarette 
smokers (39). The preferences and demand for flavoured nicotine products 
seem to apply to conventional cigarettes and EN&NNDS interchangeably. 
Users tend to seek rewards from flavours across the whole range of available 
nicotine products (40). In other words, when the desired flavour is not available 
from the desired nicotine product, a proportion of users may seek it from a 
second-choice nicotine product.
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Key messages  
and conclusions
EN&NNDS are not harmless. Although the consequences for long-term effects 
on morbidity and mortality have not yet been studied sufficiently, EN&NNDS 
are not safe for young people, pregnant women and adults who have never 
smoked. While it is expected that use of EN&NNDS in these groups might 
increase their health risks, non-pregnant adult smokers who completely switch 
from combustible tobacco cigarettes to use of unadulterated and appropriately 
regulated EN&NNDS alone might reduce their health risks. This potential has 
been recognized by WHO (41), NASEM (16) and the CDC (42). 
As indicated by WHO (41), the key to any policy on EN&NNDS is to “appropriately 
regulate these products, so as to minimize consequences that may contribute to 
the tobacco epidemic and to optimize the potential benefits to public health”, as 
well as “avoiding nicotine initiation among non-smokers and particularly youth 
while maximizing potential benefits for smokers”. To strike such a regulatory 
balance is challenging in view of the existing scientific evidence and the fact 
that not all countries will have the required regulatory and surveillance capacity 
(43). WHO Members States that decide to regulate EN&NNDS may consider 
the options below to attain the policy objectives set by the Conference of the 
Parties (COP) of the WHO FCTC, which are to (44):
 prevent the initiation of EN&NNDS by non-smokers and young people, 
with special attention to vulnerable groups;
 minimize as far as possible potential health risks to EN&NNDS users and 
protect non-users from exposure to their emissions;
 prevent unproven health claims from being made about EN&NNDS; and
 protect tobacco-control activities from all commercial and other vested 
interests related to EN&NNDS, including interests of the tobacco industry.
Countries that decide to regulate EN&NNDS should consider:
 being mindful of the unintended consequences of any regulatory measure 
in swaying the market towards any specific type of EN&NNDS product;
 regulating EN&NNDS that make health claims as medicinal products and 
therapeutic devices and authorizing their marketing once such claims have 
been verified scientifically;
 banning or restricting advertising, promotion and sponsorship of EN&NNDS, 
regulating sales channels (including online sales) and strongly enforcing 
laws on minimum age of purchase, while recognizing that restricting access 
to tobacco products for minors and adults to make it difficult to transition 
to cigarettes when using EN&NNDS is paramount; 
 minimizing health risks to EN&NNDS users by standardizing:
• the manufacture of devices and EN&NNDS components under effective 
electrical equipment safety regulations, including waste and safe 
disposal of electrical and electronic equipment;
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• the content of e-liquids, to limit the amount of nicotine available per 
cartridge or bottle and avoid some ingredients, such as carcinogens, 
mutagens or reprotoxins, those that facilitate inhalation or nicotine 
uptake and additives such as amino acids, caffeine, colouring agents, 
essential fatty acids, glucuronolactone, probiotics, taurine, vitamins and 
mineral nutrients – the existing evidence is insufficient to recommend 
banning (or not banning) certain flavours that may be attractive to 
children; and
• the packaging of e-liquids by requiring child-proof containers and 
labelling ENDS to inform users of the addictive nature of the product;
 minimizing health risks to non-users by outlawing the use of EN&NNDS 
in all indoor spaces or where smoking is prohibited until it is proven that 
the second-hand aerosol poses no health risks to bystanders;
 limiting the levels and number of specific flavours allowed in EN&NNDS 
to reduce initiation by young people; and
 setting surveillance systems to monitor the evolution in patterns of 
EN&NNDS consumption and detect health or safety incidents involving 
EN&NNDS – given the current state of knowledge about market dynamics, 
it is extremely important for countries to start monitoring EN&NNDS 
products in the market and evaluate the impact of regulation on prices 
and consumption (this includes surveillance of population patterns of 
EN&NNDS use by use intensity, type of device, the content of e-liquid and 
reason for use, and by demographic characteristics and smoking status); 
as the market is rapidly evolving, adjustments to taxation approaches may 
be needed over time.
In addition, countries that decide to impose an excise tax should consider: 
 adopting the best tax structure that the level of national tax administration, 
product regulation and tobacco-control policies determine – for example, 
countries with strong tax administration and strong product regulation 
may find the option of specific excise taxation advantageous, while those 
with strong tax administration and weak product regulation may find an 
ad valorem system is an option; 
 setting product characteristics to improve the effectiveness of any taxation 
structure, regardless of context; and
 collecting tax in the same way as for tobacco products in the country (in 
most countries, the collection is made at the source – the manufacturing/
importing point).
Some types of ENDS help some smokers quit under certain circumstances, 
but the evidence is insufficient to issue a blanket recommendation to use any 
type of EN&NNDS as a cessation aid for all smokers.
A final and important caveat regarding any EN&NNDS policy, of whatever 
nature, is that such a policy would benefit extraordinarily from the simultaneous 
implementation of a very strong tobacco-control policy to curtail any potential 
trajectory from EN&NNDS use to smoking.
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